Ginkgo Bioworks
DNA
About: Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Employees: 834
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
129% more call options, than puts
Call options by funds: $22.1M | Put options by funds: $9.65M
105% more capital invested
Capital invested by funds: $183M [Q1] → $375M (+$193M) [Q2]
67% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 5 (+2) [Q2]
35% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 34
3% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 35
0.8% more ownership
Funds ownership: 71.16% [Q1] → 71.96% (+0.8%) [Q2]
0% more funds holding
Funds holding: 165 [Q1] → 165 (+0) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
BTIG
Mark Massaro
|
$9
|
Sell
Maintained
|
25 Aug 2025 |
Financial journalist opinion
Based on 3 articles about DNA published over the past 30 days
